Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H)
Tatsuki Koike, Masato Yoshikawa, Haruhi Kamisaki Ando, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 16, pp. 12228-12244
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

An Analysis of Successful Hit-to-Clinical Candidate Pairs
Dean G. Brown
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 11, pp. 7101-7139
Closed Access | Times Cited: 29
Pathophysiology to Risk Factor and Therapeutics to Treatment Strategies on Epilepsy
Ana Paula de Araújo Boleti, Pedro Henrique de Oliveira Cardoso, Breno Emanuel Farias Frihling, et al.
Brain Sciences (2024) Vol. 14, Iss. 1, pp. 71-71
Open Access | Times Cited: 17
Current state of the epilepsy drug and device pipeline
Samuel W. Terman, Laura Kirkpatrick, Lisa F. Akiyama, et al.
Epilepsia (2024) Vol. 65, Iss. 4, pp. 833-845
Open Access | Times Cited: 15
Brain Cytochrome P450: Navigating Neurological Health and Metabolic Regulation
Pradeepraj Durairaj, Zixiang Liu
Journal of Xenobiotics (2025) Vol. 15, Iss. 2, pp. 44-44
Open Access | Times Cited: 1
Assessment of cholesterol homeostasis in the living human brain
Ahmed Haider, Chunyu Zhao, Lu Wang, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 665
Open Access | Times Cited: 26
Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies
Graeme J. Sills
Therapeutic Advances in Neurological Disorders (2023) Vol. 16
Open Access | Times Cited: 16
Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials
Amanda W. Pong, Jonathan Ross, Ivana Tyrlíková, et al.
Expert Opinion on Emerging Drugs (2022) Vol. 27, Iss. 1, pp. 75-90
Closed Access | Times Cited: 22
Inflammatory signaling on cytochrome P450-mediated drug metabolism in hepatocytes
Xiaokang Wang, Jiaoyu Rao, Zhiyi Tan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 22
Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis
Jian Wu, Liu Zhang, Xi Zhou, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
4-hydroxypiperidines containing a quaternary stereocenter by aza-Prins cyclization
Myriam Le Roch, Nicolas Gouault, Jacques Renault, et al.
Organic & Biomolecular Chemistry (2025)
Closed Access
Conformational analysis of soticlestat, an inhibitor of CYP46A1 (CH24H), and its derivatives by variable-temperature nmr and computational methods
Wenqian Huang, Xinwei Hu, Xiaotong Lin, et al.
Structural Chemistry (2025)
Closed Access
A review of the putative antiseizure and antiepileptogenic mechanisms of action for soticlestat
Shinichi Kondo, Venkatesha Murthy, Mahnaz Asgharnejad, et al.
Epilepsia (2025)
Open Access
Spotlight on mechanism of sudden unexpected death in epilepsy in Dravet syndrome
WeiHui Shao, Lu Liu, JiaXuan Gu, et al.
Translational Psychiatry (2025) Vol. 15, Iss. 1
Open Access
Design and identification of brain-penetrant, potent, and selective 1,3-oxazole-based cholesterol 24-hydroxylase (CH24H) inhibitors
Y. ITO, Eiji Kimura, Izumi Nomura, et al.
Bioorganic & Medicinal Chemistry (2025), pp. 118182-118182
Open Access
Tertiary Alcohol: Reaping the Benefits but Minimizing the Drawbacks of Hydroxy Groups in Drug Discovery
Debora Chiodi, Yoshihiro Ishihara
Journal of Medicinal Chemistry (2025)
Closed Access
Structure-Based Design of a Novel Series of Cholesterol 24-Hydroxylase (Ch24h) Inhibitors Bearing 1,3-Oxazole as a Heme-Iron Binding Group
Y. ITO, Tomoaki Hasui, Eiji Kimura, et al.
(2025)
Closed Access
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
Shining Wang, Grace Chen, Emilio Merlo Pich, et al.
British Journal of Clinical Pharmacology (2022) Vol. 88, Iss. 6, pp. 2899-2908
Open Access | Times Cited: 16
Scaffold-Retained Structure Generator to Exhaustively Create Molecules in an Arbitrary Chemical Space
Kazuma Kaitoh, Yoshihiro Yamanishi
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 9, pp. 2212-2225
Closed Access | Times Cited: 15
Unbiased insights into the multiplicity of the CYP46A1 brain effects in 5XFAD mice treated with low dose-efavirenz
Natalia Mast, Makaya Butts, Irina A. Pikuleva
Journal of Lipid Research (2024) Vol. 65, Iss. 6, pp. 100555-100555
Open Access | Times Cited: 3
Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis
Melissa Barker‐Haliski, Nicole A. Hawkins
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1099-1113
Closed Access | Times Cited: 3
Cholesterol 24-hydroxylase is a novel pharmacological target for anti-ictogenic and disease modification effects in epilepsy
Alessia Salamone, Gaetano Terrone, Rossella Di Sapia, et al.
Neurobiology of Disease (2022) Vol. 173, pp. 105835-105835
Open Access | Times Cited: 13
Discovery of Novel 3-Piperidinyl Pyridine Derivatives as Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors
Y. Kajita, Shuhei Ikeda, Masato Yoshikawa, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 4, pp. 3343-3358
Closed Access | Times Cited: 11
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, modifies acute seizure burden and chronic epilepsy-related behavioral deficits following Theiler's virus infection in mice
Melissa Barker‐Haliski, Toshiya Nishi, H. Steve White
Neuropharmacology (2022) Vol. 222, pp. 109310-109310
Open Access | Times Cited: 11
Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24‐hydroxylase inhibitor soticlestat in healthy volunteers
Wei Yin, T. Eric Ballard, Xiaochun Zhu, et al.
British Journal of Clinical Pharmacology (2023) Vol. 90, Iss. 2, pp. 516-527
Open Access | Times Cited: 6
Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function
Wei Yin, P. P. Mitra, Veronique Copalu, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top